VRTX vs INCY — Key Metrics
| Metric | VRTX (VERTEX PHARMACEUTICALS INC) | INCY (INCYTE CORP) |
|---|---|---|
| Price | 522.81 | 121.35 |
| Market Cap | 132.51 Billion | 24.6 Billion |
| P/E (TTM) | 30.17 | 14.94 |
| P/B (Quarterly) | 5.992 | 4.151 |
| P/S (TTM) | 10.53 | 4.23 |
| Net Profit Margin (TTM) | 35.0 | 27.7 |
| Gross Margin (TTM) | 86.0 | 92.6 |
| ROE (TTM) | 23.3 | 29.6 |
| Revenue Growth YoY (TTM) | None | None |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
VRTX · VERTEX PHARMACEUTICALS INC
Outperform
INCY · INCYTE CORP
Greatly Outperform
Recommendation Summary
Stock VRTX is projected to outperform the market, stock INCY is projected to greatly outperform the market. Upfront Recommendation: INCY.
Financial Metrics
Prices delayed ~15 min
| VRTX | Metrics | INCY |
|---|---|---|
| $522.81 | Price | $121.35 |
| — | Market Capitalization | — |
| 30.17 | Price to Earnings Ratio | 14.94 |
| 10.53 | Price to Sales | 4.23 |
| 34.91 | Price to FCF Ratio | 12.81 |
| 12.24 | Price to Gross Profit | 4.56 |
| 33.92 | Price to R&D | 11.44 |
| 10.56 | Price to Current Assets | 4.08 |